Paul J. Diaz has been one of our directors since July 2007. Since August 2020, Mr. Diaz has served as president, chief executive officer (CEO) and member of the board of directors for Myriad Genetics, Inc., a molecular diagnostic company. From August 2017 to August 2020, Mr. Diaz was a partner at Cressey & Company LP, a private equity firm focused exclusively on investing in and building health care businesses, and currently serves as a partner emeritus and a member of its Distinguished Executive Council. Since August 2014, Mr. Diaz has served as founding partner at Guidon Partners LP, a private investment partnership. Mr. Diaz served as executive vice chairman of Kindred Healthcare, Inc. (“Kindred”), a post-acute provider in the United States, which includes transitional care and rehabilitation hospitals, sub-acute units, and home healthcare and hospice agencies, from March 2015 to March 2016, CEO from January 2004 to March 2015, president from January 2002 to May 2012 and chief operating officer from January 2002 to December 2003.Prior to joining Kindred, Mr. Diaz was the managing member of Falcon Capital Partners, LLC, a private investment and consulting firm. From 1996 to 1998, Mr. Diaz served in various executive capacities, including as executive vice president and chief operating officer, with Mariner Health Group, Inc., a national provider of long-term care facilities, rehabilitation services and institutional pharmacies. Mr. Diaz serves on the board of trustees of Johns Hopkins Medicine. Mr. Diaz formerly served on the board of directors of PharMerica Corporation, Kindred, the Federation of American Hospitals and the Bloomberg School of Public Health at John Hopkins University.
What is Paul J. Diaz's net worth?
The estimated net worth of Paul J. Diaz is at least $2.10 million as of May 18th, 2020. Mr. Diaz owns 15,749 shares of DaVita stock worth more than $2,102,177 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Diaz may own. Learn More about Paul J. Diaz's net worth.
How do I contact Paul J. Diaz?
Has Paul J. Diaz been buying or selling shares of DaVita?
Paul J. Diaz has not been actively trading shares of DaVita in the last ninety days. Most recently, Paul J. Diaz sold 5,763 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $82.22, for a transaction totalling $473,833.86. Following the completion of the sale, the director now directly owns 15,749 shares of the company's stock, valued at $1,294,882.78. Learn More on Paul J. Diaz's trading history.
Who are DaVita's active insiders?
DaVita's insider roster includes Joel Ackerman (CFO), Pamela Arway (Director), Charles Berg (Director), Barbara Desoer (Director), Paul Diaz (Director), John Nehra (Director), Paula Price (Director), Javier Rodriguez (CEO), Michael Staffieri (COO), Kathleen Waters (Insider), and Phyllis Yale (Director). Learn More on DaVita's active insiders.
Are insiders buying or selling shares of DaVita?
In the last year, insiders at the sold shares 9 times. They sold a total of 181,836 shares worth more than $21,270,343.49. The most recent insider tranaction occured on February, 26th when CEO Javier Rodriguez sold 67,603 shares worth more than $8,525,414.33. Insiders at DaVita own 1.4% of the company.
Learn More about insider trades at DaVita. Information on this page was last updated on 2/26/2024.
